Validated spectrofluorimetric methods for the determination of apixaban and tirofiban hydrochloride in pharmaceutical formulations
Apixaban and Tirofiban Hydrochloride are low molecular weight anticoagulants. The two drugs exhibit native fluorescence that allow the development of simple and valid spectrofluorimetric methods for the determination of Apixaban at λ ex/λ em=284/450nm and tirofiban HCl at λ ex/λ em=227/300nm in aque...
Saved in:
Published in | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy Vol. 174; pp. 326 - 330 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier B.V
05.03.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Apixaban and Tirofiban Hydrochloride are low molecular weight anticoagulants. The two drugs exhibit native fluorescence that allow the development of simple and valid spectrofluorimetric methods for the determination of Apixaban at λ ex/λ em=284/450nm and tirofiban HCl at λ ex/λ em=227/300nm in aqueous media. Different experimental parameters affecting fluorescence intensities were carefully studied and optimized. The fluorescence intensity-concentration plots were linear over the ranges of 0.2–6μgml−1 for apixaban and 0.2–5μgml−1 for tirofiban HCl. The limits of detection were 0.017 and 0.019μgml−1 and quantification limits were 0.057 and 0.066μgml−1 for apixaban and tirofiban HCl, respectively. The fluorescence quantum yield of apixaban and tirofiban were calculated with values of 0.43 and 0.49. Method validation was evaluated for linearity, specificity, accuracy, precision and robustness as per ICH guidelines. The proposed spectrofluorimetric methods were successfully applied for the determination of apixaban in Eliquis tablets and tirofiban HCl in Aggrastat intravenous infusion. Tolerance ratio was tested to study the effect of foreign interferences from dosage forms excipients. Using Student's t and F tests, revealed no statistically difference between the developed spectrofluorimetric methods and the comparison methods regarding the accuracy and precision, so can be contributed to the analysis of apixaban and tirofiban HCl in QC laboratories as an alternative method.
[Display omitted]
•New validated spectrofluorimetric methods for the analysis of selected anticoagulants.•The developed methods are successfully applied for the analysis of selected drugs in drug substances and drug products.•The methods are based on the measurements of the native fluorescence of selected drugs.•The proposed methods can be used as alternative methods in quality control laboratories. |
---|---|
AbstractList | Apixaban and Tirofiban Hydrochloride are low molecular weight anticoagulants. The two drugs exhibit native fluorescence that allow the development of simple and valid spectrofluorimetric methods for the determination of Apixaban at λ ex/λ em=284/450nm and tirofiban HCl at λ ex/λ em=227/300nm in aqueous media. Different experimental parameters affecting fluorescence intensities were carefully studied and optimized. The fluorescence intensity-concentration plots were linear over the ranges of 0.2-6μgml
for apixaban and 0.2-5μgml
for tirofiban HCl. The limits of detection were 0.017 and 0.019μgml
and quantification limits were 0.057 and 0.066μgml
for apixaban and tirofiban HCl, respectively. The fluorescence quantum yield of apixaban and tirofiban were calculated with values of 0.43 and 0.49. Method validation was evaluated for linearity, specificity, accuracy, precision and robustness as per ICH guidelines. The proposed spectrofluorimetric methods were successfully applied for the determination of apixaban in Eliquis tablets and tirofiban HCl in Aggrastat intravenous infusion. Tolerance ratio was tested to study the effect of foreign interferences from dosage forms excipients. Using Student's t and F tests, revealed no statistically difference between the developed spectrofluorimetric methods and the comparison methods regarding the accuracy and precision, so can be contributed to the analysis of apixaban and tirofiban HCl in QC laboratories as an alternative method. Apixaban and Tirofiban Hydrochloride are low molecular weight anticoagulants. The two drugs exhibit native fluorescence that allow the development of simple and valid spectrofluorimetric methods for the determination of Apixaban at λ ex/λ em=284/450nm and tirofiban HCl at λ ex/λ em=227/300nm in aqueous media. Different experimental parameters affecting fluorescence intensities were carefully studied and optimized. The fluorescence intensity-concentration plots were linear over the ranges of 0.2–6μgml−1 for apixaban and 0.2–5μgml−1 for tirofiban HCl. The limits of detection were 0.017 and 0.019μgml−1 and quantification limits were 0.057 and 0.066μgml−1 for apixaban and tirofiban HCl, respectively. The fluorescence quantum yield of apixaban and tirofiban were calculated with values of 0.43 and 0.49. Method validation was evaluated for linearity, specificity, accuracy, precision and robustness as per ICH guidelines. The proposed spectrofluorimetric methods were successfully applied for the determination of apixaban in Eliquis tablets and tirofiban HCl in Aggrastat intravenous infusion. Tolerance ratio was tested to study the effect of foreign interferences from dosage forms excipients. Using Student's t and F tests, revealed no statistically difference between the developed spectrofluorimetric methods and the comparison methods regarding the accuracy and precision, so can be contributed to the analysis of apixaban and tirofiban HCl in QC laboratories as an alternative method. [Display omitted] •New validated spectrofluorimetric methods for the analysis of selected anticoagulants.•The developed methods are successfully applied for the analysis of selected drugs in drug substances and drug products.•The methods are based on the measurements of the native fluorescence of selected drugs.•The proposed methods can be used as alternative methods in quality control laboratories. |
Author | Elkady, Ehab F. El-Bagary, Ramzia I. Youssef, Nadia F. Farid, Naira A. |
Author_xml | – sequence: 1 givenname: Ramzia I. surname: El-Bagary fullname: El-Bagary, Ramzia I. organization: Pharmaceutical Chemistry Department, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University, Egypt – sequence: 2 givenname: Ehab F. surname: Elkady fullname: Elkady, Ehab F. organization: Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Egypt – sequence: 3 givenname: Naira A. surname: Farid fullname: Farid, Naira A. email: nairaahmed49@yahoo.com organization: Pharmaceutical Chemistry Department, National organization for Drug Control and Research (NODCAR), Giza, Egypt – sequence: 4 givenname: Nadia F. surname: Youssef fullname: Youssef, Nadia F. organization: Pharmaceutical Chemistry Department, National organization for Drug Control and Research (NODCAR), Giza, Egypt |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27984753$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kMtqHDEQRUWwyXhsf0A2QT_QbZXUDw1ZBZOHweCN7a3Qo5rW0N1qJE2It_lyazKJl15VFdQ9VJ0tOVvCgoR8AlYDg-5mXyeta17aGqBmjfxALkD2ohJt25-VXsiugoa3G7JNac8YA8nZR7Lh_U42fSsuyJ9nPXmnMzqaVrQ5hmE6hOhnzNFbWsoYXKJDiDSPSB1mjLNfdPZhoWGgevW_tdEL1Yuj2Ze4P07ji4vBjlMhOaR-oeuo46wtHrK3ejry5sP0l5KuyPmgp4TX_-olefr-7fH2Z3X_8OPu9ut9ZUUrcmUGBtwK7LjegZUdSCP61rTcDD3jojFGDrw3fYccTMuYlDswrtFSQoOsPHtJ4MS1MaQUcVBr-VPHFwVMHX2qvSo-1dGnAlDFZ8l8PmXWg5nRvSX-CywLX04LWC7_5TGqZD0uFp2PRadywb-DfwVoHotA |
CitedBy_id | crossref_primary_10_1016_j_saa_2023_122473 crossref_primary_10_1016_j_pharma_2021_06_002 crossref_primary_10_1021_acsomega_2c07790 crossref_primary_10_1515_revac_2023_0058 crossref_primary_10_1007_s10895_020_02616_w crossref_primary_10_1016_j_saa_2018_11_028 crossref_primary_10_1038_s41598_022_25917_5 crossref_primary_10_1039_D3RA03293K crossref_primary_10_1016_j_saa_2021_120207 crossref_primary_10_1016_j_molliq_2017_10_139 crossref_primary_10_1002_bmc_4719 crossref_primary_10_1155_2024_2675736 crossref_primary_10_1016_j_nantod_2021_101186 |
Cites_doi | 10.1016/S0731-7085(96)01848-1 10.1016/j.jpba.2013.02.007 10.1016/j.saa.2016.01.029 10.1016/j.jchromb.2004.03.003 10.4236/ajac.2015.66052 10.3797/scipharm.1403-25 |
ContentType | Journal Article |
Copyright | 2016 Elsevier B.V. Copyright © 2016 Elsevier B.V. All rights reserved. |
Copyright_xml | – notice: 2016 Elsevier B.V. – notice: Copyright © 2016 Elsevier B.V. All rights reserved. |
DBID | NPM AAYXX CITATION |
DOI | 10.1016/j.saa.2016.11.048 |
DatabaseName | PubMed CrossRef |
DatabaseTitle | PubMed CrossRef |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry Physics |
EISSN | 1873-3557 |
EndPage | 330 |
ExternalDocumentID | 10_1016_j_saa_2016_11_048 27984753 S1386142516307119 |
Genre | Journal Article |
GroupedDBID | --- --K --M .~1 0R~ 123 1B1 1~. 1~5 4.4 457 4G. 5VS 7-5 71M 8P~ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AARLI AAXUO ABMAC ABYKQ ACDAQ ACRLP ADBBV ADECG ADEZE AEBSH AEKER AFKWA AFTJW AFZHZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV AJSZI ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC CS3 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FIRID FLBIZ FNPLU FYGXN G-Q GBLVA HVGLF IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 RIG RNS ROL RPZ SCB SDF SDG SDP SES SPC SPCBC SSK SSZ T5K WH7 XPP ZMT ~G- NPM 1RT 53G 6TJ AAQXK AAXKI AAYXX ABFNM ABXDB ACNNM ADMUD AFJKZ ASPBG AVWKF AZFZN CITATION FGOYB HZ~ M36 R2- SEW UHS |
ID | FETCH-LOGICAL-c353t-bf012c3e62a91c8618b375b52bf70234bb8f27b76e21b5008891bd4a8814e0753 |
IEDL.DBID | AIKHN |
ISSN | 1386-1425 |
IngestDate | Thu Sep 26 16:17:26 EDT 2024 Wed Oct 16 01:00:25 EDT 2024 Fri Feb 23 02:32:01 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Tirofiban HCl Method validation Spectrofluorimetry Apixaban Pharmaceutical formulations |
Language | English |
License | Copyright © 2016 Elsevier B.V. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c353t-bf012c3e62a91c8618b375b52bf70234bb8f27b76e21b5008891bd4a8814e0753 |
PMID | 27984753 |
PageCount | 5 |
ParticipantIDs | crossref_primary_10_1016_j_saa_2016_11_048 pubmed_primary_27984753 elsevier_sciencedirect_doi_10_1016_j_saa_2016_11_048 |
PublicationCentury | 2000 |
PublicationDate | 2017-03-05 |
PublicationDateYYYYMMDD | 2017-03-05 |
PublicationDate_xml | – month: 03 year: 2017 text: 2017-03-05 day: 05 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy |
PublicationTitleAlternate | Spectrochim Acta A Mol Biomol Spectrosc |
PublicationYear | 2017 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Țilea, Popa, Xantus, Primejdie, Grigorescu, Țilea, Bocicor, Varga (bb0035) 2015; 23 Brayfield (bb0005) 2014 Brunton, Chabner, Knollman, Weitz (bb0010) 2011 Gandhimathi, Athotiand, Ravi (bb0050) 2013; 3 Tantawy, El-Ragehy, Hassan, Abdelkawy (bb0020) 2016; 159 bb0095 Agarwal (bb0110) 2013; 279 Chen, Huang, Zheng, Xu, Wang (bb0090) 1990; 17 PRABHUNE, JAGUSTE, KONDALKAR, PRADHAN (bb0025) 2014; 82 Darkovska, Emilija, Zorica, Icko, Nenad (bb0060) 2014; 4 Rong-fu, Chi, Jun-feng, Qing (bb0045) 2010 Ellis, Hand, Gilbert (bb0075) 1997; 15 Delavenne, Mismetti, Basset (bb0040) 2013; 78–79 Katzung, Masters, Trevor, Zehnder (bb0015) 2012 Ranjitha, Rao (bb0055) 2011; 1 NATARAJ, SAI KUMAR, KALYANI, DUZA (bb0070) 2013; 5 (bb0100) 2015 Oertel, Kohler, Koste, Kirch (bb0080) 2004; 805 International conference on Harmonization (ICH) Q2 (bb0085) 2005 Yang-jie, Lei, Qi-ming (bb0065) 2013; 33 Landge, Jadhav, Dahale, Solanki, Bembalkar, Mathad (bb0030) 2015; 6 (bb0105) 2015 28315823 - Spectrochim Acta A Mol Biomol Spectrosc. 2017 Jun 15;181:23 PRABHUNE (10.1016/j.saa.2016.11.048_bb0025) 2014; 82 Ranjitha (10.1016/j.saa.2016.11.048_bb0055) 2011; 1 Agarwal (10.1016/j.saa.2016.11.048_bb0110) 2013; 279 (10.1016/j.saa.2016.11.048_bb0105) 2015 Brayfield (10.1016/j.saa.2016.11.048_bb0005) 2014 Rong-fu (10.1016/j.saa.2016.11.048_bb0045) 2010 NATARAJ (10.1016/j.saa.2016.11.048_bb0070) 2013; 5 Delavenne (10.1016/j.saa.2016.11.048_bb0040) 2013; 78–79 Chen (10.1016/j.saa.2016.11.048_bb0090) 1990; 17 (10.1016/j.saa.2016.11.048_bb0100) 2015 Ellis (10.1016/j.saa.2016.11.048_bb0075) 1997; 15 Țilea (10.1016/j.saa.2016.11.048_bb0035) 2015; 23 Darkovska (10.1016/j.saa.2016.11.048_bb0060) 2014; 4 Brunton (10.1016/j.saa.2016.11.048_bb0010) 2011 International conference on Harmonization (ICH) Q2 (10.1016/j.saa.2016.11.048_bb0085) 2005 Yang-jie (10.1016/j.saa.2016.11.048_bb0065) 2013; 33 Tantawy (10.1016/j.saa.2016.11.048_bb0020) 2016; 159 Katzung (10.1016/j.saa.2016.11.048_bb0015) 2012 Oertel (10.1016/j.saa.2016.11.048_bb0080) 2004; 805 Landge (10.1016/j.saa.2016.11.048_bb0030) 2015; 6 Gandhimathi (10.1016/j.saa.2016.11.048_bb0050) 2013; 3 |
References_xml | – year: 2015 ident: bb0100 article-title: In-house Specification for the Analysis of Apixaban publication-title: Megafine – volume: 33 start-page: 1012 year: 2013 end-page: 1015 ident: bb0065 article-title: HPLC determination of tirofiban using chiral mobile phase publication-title: Chinese Journal of Pharmaceutical Analysis contributor: fullname: Qi-ming – start-page: 601 year: 2012 ident: bb0015 article-title: Basic & Clinical Pharmacology, 12th ed contributor: fullname: Zehnder – volume: 3 start-page: 9310 year: 2013 end-page: 9315 ident: bb0050 article-title: Three newer methods for the estimation of tirofiban hydrochloride from pharmaceutical formulation publication-title: IAJPR contributor: fullname: Ravi – volume: 279 start-page: 189 year: 2013 ident: bb0110 article-title: Basic Statistics contributor: fullname: Agarwal – volume: 78–79 start-page: 150 year: 2013 end-page: 153 ident: bb0040 article-title: Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study publication-title: J. Pharm. Biomed. Anal. contributor: fullname: Basset – volume: 4 start-page: 115 year: 2014 end-page: 120 ident: bb0060 article-title: Development and validation of reverse phase high performance liquid chromatographic method for determination of tirofiban in serum publication-title: IJPP contributor: fullname: Nenad – volume: 23 start-page: 115 year: 2015 end-page: 125 ident: bb0035 article-title: Determination of apixaban levels in human plasma by a high-throughput liquid chromatographic tandem mass spectrometry assay publication-title: RJLabM contributor: fullname: Varga – year: 2010 ident: bb0045 article-title: Determination of tirofiban hydrochloride/sodium chloride injection by UV spectrophotometry publication-title: Journal of china pharmacy contributor: fullname: Qing – year: 2005 ident: bb0085 article-title: (R1): Validation of Analytical Procedures Test and Methodology, Geneva, Switzerland contributor: fullname: International conference on Harmonization (ICH) Q2 – volume: 6 start-page: 539 year: 2015 end-page: 550 ident: bb0030 article-title: Development and validation of stability indicating RP-HPLC method on core shell column for determination of degradation and process related impurities of apixaban—an anticoagulant drug publication-title: AJAC contributor: fullname: Mathad – volume: 1 start-page: 43 year: 2011 end-page: 47 ident: bb0055 article-title: Development and validation of new rp-hplc method for the determination of tirofiban in pharmaceutical formulation publication-title: IJPCBS contributor: fullname: Rao – volume: 805 start-page: 181 year: 2004 end-page: 185 ident: bb0080 article-title: Determination of tirofiban in human serum by liquid chromatography–tandem mass spectrometry publication-title: J. Chromatogr. B contributor: fullname: Kirch – year: 2015 ident: bb0105 article-title: In-house Specification for the Analysis of Tirofiban publication-title: Gland chemical private LTD – start-page: 849 year: 2011 ident: bb0010 article-title: Goodman&Gliman's: The pharmacological Basis of Therapeutics, 12th ed contributor: fullname: Weitz – volume: 82 start-page: 777 year: 2014 end-page: 785 ident: bb0025 article-title: Stability-indicating high-performance liquid chromatographic determination of apixaban in the presence of degradation products publication-title: Sci. Pharm. contributor: fullname: PRADHAN – volume: 15 start-page: 561 year: 1997 end-page: 569 ident: bb0075 article-title: Use of LC-MS/MS to cross-validate a radioimmunoassay for the fibrinogen receptor antagonist, Aggrastat (tirofiban hydrochloride) in human plasma publication-title: J Pharm Biomed Anal contributor: fullname: Gilbert – volume: 159 start-page: 13 year: 2016 end-page: 20 ident: bb0020 article-title: Stability-indicating spectrophotometric methods for determination of the anticoagulant drug apixaban in the presence of its hydrolytic degradation product publication-title: Spectrochim. Acta: Part A, Molecular and Biomolecular Spectroscopy contributor: fullname: Abdelkawy – volume: 5 start-page: 200 year: 2013 end-page: 203 ident: bb0070 article-title: Development and validation of a reverse phase high performance liquid chromatographic method for the estimation of tirofiban in pharmaceutical dosage forms publication-title: Int J Ph Ph Sci contributor: fullname: DUZA – year: 2014 ident: bb0005 article-title: Martindale: the Complete Drug Reference, 38th ed, volume A contributor: fullname: Brayfield – volume: 17 year: 1990 ident: bb0090 article-title: Method of Fluorescence Analysis contributor: fullname: Wang – ident: bb0095 – volume: 23 start-page: 115 issue: 1 year: 2015 ident: 10.1016/j.saa.2016.11.048_bb0035 article-title: Determination of apixaban levels in human plasma by a high-throughput liquid chromatographic tandem mass spectrometry assay publication-title: RJLabM contributor: fullname: Țilea – volume: 15 start-page: 561 issue: 5 year: 1997 ident: 10.1016/j.saa.2016.11.048_bb0075 article-title: Use of LC-MS/MS to cross-validate a radioimmunoassay for the fibrinogen receptor antagonist, Aggrastat (tirofiban hydrochloride) in human plasma publication-title: J Pharm Biomed Anal doi: 10.1016/S0731-7085(96)01848-1 contributor: fullname: Ellis – start-page: 601 year: 2012 ident: 10.1016/j.saa.2016.11.048_bb0015 contributor: fullname: Katzung – start-page: 849 year: 2011 ident: 10.1016/j.saa.2016.11.048_bb0010 contributor: fullname: Brunton – volume: 78–79 start-page: 150 year: 2013 ident: 10.1016/j.saa.2016.11.048_bb0040 article-title: Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study publication-title: J. Pharm. Biomed. Anal. doi: 10.1016/j.jpba.2013.02.007 contributor: fullname: Delavenne – volume: 159 start-page: 13 year: 2016 ident: 10.1016/j.saa.2016.11.048_bb0020 article-title: Stability-indicating spectrophotometric methods for determination of the anticoagulant drug apixaban in the presence of its hydrolytic degradation product publication-title: Spectrochim. Acta: Part A, Molecular and Biomolecular Spectroscopy doi: 10.1016/j.saa.2016.01.029 contributor: fullname: Tantawy – volume: 1 start-page: 43 issue: 1 year: 2011 ident: 10.1016/j.saa.2016.11.048_bb0055 article-title: Development and validation of new rp-hplc method for the determination of tirofiban in pharmaceutical formulation publication-title: IJPCBS contributor: fullname: Ranjitha – volume: 5 start-page: 200 issue: 1 year: 2013 ident: 10.1016/j.saa.2016.11.048_bb0070 article-title: Development and validation of a reverse phase high performance liquid chromatographic method for the estimation of tirofiban in pharmaceutical dosage forms publication-title: Int J Ph Ph Sci contributor: fullname: NATARAJ – year: 2015 ident: 10.1016/j.saa.2016.11.048_bb0100 article-title: In-house Specification for the Analysis of Apixaban publication-title: Megafine – volume: 805 start-page: 181 issue: 1 year: 2004 ident: 10.1016/j.saa.2016.11.048_bb0080 article-title: Determination of tirofiban in human serum by liquid chromatography–tandem mass spectrometry publication-title: J. Chromatogr. B doi: 10.1016/j.jchromb.2004.03.003 contributor: fullname: Oertel – volume: 17 year: 1990 ident: 10.1016/j.saa.2016.11.048_bb0090 contributor: fullname: Chen – year: 2015 ident: 10.1016/j.saa.2016.11.048_bb0105 article-title: In-house Specification for the Analysis of Tirofiban publication-title: Gland chemical private LTD – year: 2010 ident: 10.1016/j.saa.2016.11.048_bb0045 article-title: Determination of tirofiban hydrochloride/sodium chloride injection by UV spectrophotometry publication-title: Journal of china pharmacy contributor: fullname: Rong-fu – volume: 6 start-page: 539 year: 2015 ident: 10.1016/j.saa.2016.11.048_bb0030 article-title: Development and validation of stability indicating RP-HPLC method on core shell column for determination of degradation and process related impurities of apixaban—an anticoagulant drug publication-title: AJAC doi: 10.4236/ajac.2015.66052 contributor: fullname: Landge – volume: 3 start-page: 9310 issue: 11 year: 2013 ident: 10.1016/j.saa.2016.11.048_bb0050 article-title: Three newer methods for the estimation of tirofiban hydrochloride from pharmaceutical formulation publication-title: IAJPR contributor: fullname: Gandhimathi – volume: 82 start-page: 777 year: 2014 ident: 10.1016/j.saa.2016.11.048_bb0025 article-title: Stability-indicating high-performance liquid chromatographic determination of apixaban in the presence of degradation products publication-title: Sci. Pharm. doi: 10.3797/scipharm.1403-25 contributor: fullname: PRABHUNE – volume: 33 start-page: 1012 issue: 6 year: 2013 ident: 10.1016/j.saa.2016.11.048_bb0065 article-title: HPLC determination of tirofiban using chiral mobile phase publication-title: Chinese Journal of Pharmaceutical Analysis contributor: fullname: Yang-jie – year: 2005 ident: 10.1016/j.saa.2016.11.048_bb0085 contributor: fullname: International conference on Harmonization (ICH) Q2 – year: 2014 ident: 10.1016/j.saa.2016.11.048_bb0005 contributor: fullname: Brayfield – volume: 4 start-page: 115 issue: 4 year: 2014 ident: 10.1016/j.saa.2016.11.048_bb0060 article-title: Development and validation of reverse phase high performance liquid chromatographic method for determination of tirofiban in serum publication-title: IJPP contributor: fullname: Darkovska – volume: 279 start-page: 189 year: 2013 ident: 10.1016/j.saa.2016.11.048_bb0110 contributor: fullname: Agarwal |
SSID | ssj0001820 |
Score | 2.307776 |
Snippet | Apixaban and Tirofiban Hydrochloride are low molecular weight anticoagulants. The two drugs exhibit native fluorescence that allow the development of simple... |
SourceID | crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 326 |
SubjectTerms | Apixaban Method validation Pharmaceutical formulations Spectrofluorimetry Tirofiban HCl |
Title | Validated spectrofluorimetric methods for the determination of apixaban and tirofiban hydrochloride in pharmaceutical formulations |
URI | https://dx.doi.org/10.1016/j.saa.2016.11.048 https://www.ncbi.nlm.nih.gov/pubmed/27984753 |
Volume | 174 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PT9swFH5iRdO4TFC2wTaQDztNSlvbceIcUTVUQK2QtqLeIjt21CBIq7VIcOHAX7738qMqFw47RY5kJ3rPet97yefvAfzIlBtECU8CI6IkCGWuAm1zHUiTOGGwIlGVmM54Eo2m4eVMzXZg2J6FIVplE_vrmF5F6-ZOv7Fmf1kU_d9casQWxOcI9ykn6c9dhCOhO7B7dnE1mmwCMmmUV3WXjgKa0P7crGheK0PqQzzqkZYndQF6E562sOd8Hz42SSM7q9_rAHZ82YUPw7ZXWxfeV0TObHUILzeYWFMV71h1iBLD7N3DgjT8SYqf1Q2jVwxTVYapH3MtG4b8wxY5M8vi0VhTMlM6ti6oozeN5k-OemsRXc95VpRsOd_-Fk7r3TeNwFafYHr-689wFDR9FoJMKrkObI4olUkfCZPwDI2qrYyVVcLmMUJ6aK3ORWzjyAtu1YCIUdy60GjNQ48ph_wMnXJR-iNgbuD0wKsYr3Tq1VjSspEe40KsRBbyY_jZmjdd1nIaacszu03RFyn5AsuSFH1xDGHrgPTVnkgx3L817UvtrM0TRJwgCCv59f8W_AZ7gsCcmGfqO3TWfx_8CaYia3sK73rP_LTZcDiaXI__AQaB3sk |
link.rule.ids | 315,783,787,4509,24128,27936,27937,45597,45691 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwELZQESoLgvIqTw9MSKG1HSfOWFWglkIXHuoW2bGjBkFa0SLByi_nLg8ECwNTlEh2Ip9z313y3XeEnCXSdoOIRZ7mQeT5IpWeMqnyhI4s15CRyEJM53YcDB7864mcrJB-XQuDtMrK95c-vfDW1ZVOtZqdeZZ17phQgC2AzwHsU4bSn6sQDUTwdq72hqPB-Nsho0Z5kXepwMMB9c_Ngua10Kg-xIIL1PLELkB_wtMP7LnaJBtV0Eh75XNtkRWXt0izX_dqa5G1gsiZLLbJ5yME1pjFW1oUUYKbfX6boYY_SvHTsmH0gkKoSiH0o7Zmw6B96Cylep69a6NzqnNLlxl29Maz6YfF3lpI17OOZjmdT39-C8f5XqpGYIsd8nB1ed8feFWfBS8RUiw9kwJKJcIFXEcsgUVVRoTSSG7SECDdN0alPDRh4DgzsovEKGasr5VivoOQQ-ySRj7L3T6htmtV18kQjlj1qg1q2QgHfiGUPPFZm5zXyxvPSzmNuOaZPcVgixhtAWlJDLZoE782QPxrT8Tg7v8atlca6_sOPIwAhKU4-N-Ep6Q5uL-9iW-G49EhWecI7MhCk0eksXx9c8cQlizNSbXtvgAwwd-x |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Validated+spectrofluorimetric+methods+for+the+determination+of+apixaban+and+tirofiban+hydrochloride+in+pharmaceutical+formulations&rft.jtitle=Spectrochimica+acta.+Part+A%2C+Molecular+and+biomolecular+spectroscopy&rft.au=El-Bagary%2C+Ramzia+I.&rft.au=Elkady%2C+Ehab+F.&rft.au=Farid%2C+Naira+A.&rft.au=Youssef%2C+Nadia+F.&rft.date=2017-03-05&rft.issn=1386-1425&rft.volume=174&rft.spage=326&rft.epage=330&rft_id=info:doi/10.1016%2Fj.saa.2016.11.048&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_saa_2016_11_048 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1386-1425&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1386-1425&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1386-1425&client=summon |